Demetrios Braddock, MD, PhD
Associate Professor of PathologyCards
About
Titles
Associate Professor of Pathology
Biography
Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004 where he practices hematopathology and heads a laboratory studying pathogenic mechanisms of severe and poorly addressed human diseases. His laboratory focuses on rare diseases of children, and on the design and engineering of novel biologics to modulate disease outcomes.
Dr. Braddock’s laboratory has designed and validated an enzyme biologic for a lethal infantile calcification disorder called ‘Generalized Arterial Calcification of Infancy’ (GACI), which has been translated into infants, children, and adults with GACI, ARHR2, PXE, and CKD-MBD (ClinicalTrials.gov: NCT05734196, NCT06046820, NCT04686175, NCT06283589).
Appointments
Pathology
Associate Professor on TermPrimary
Other Departments & Organizations
- Biochemistry, Quantitative Biology, Biophysics and Structural Biology (BQBS)
- Braddock Lab
- Dean's Workshops
- Discovery to Cure Internship
- Genomics, Genetics, and Epigenetics
- Hematopathology
- Hematopathology
- Molecular Medicine, Pharmacology, and Physiology
- Pathology
- Pathology and Molecular Medicine
- Pathology Research
- Program in Translational Biomedicine (PTB)
- Prostate & Urologic Cancers Program
- Structural Biology
- Surgical Pathology
- Vascular Biology and Therapeutics Program
- Yale Cancer Center
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Medicine
- Yale Ventures
Education & Training
- Fellow
- Yale University School of Medicine (2010)
- Resident
- National Cancer Institute, NIH, Laboratory of Pathology (2000)
- MD
- University of Chicago Pritzker School of Medicine (1996)
- PhD
- University of Chicago (1994)
Research
Overview
My group is primarily interested in biochemical and structural pathogenesis of blood disorders and protein engineering, and have focused our work on understanding the physiologic role of the ENPP family of enzymes. We recently described two members of the ENPP family in brain vasculature that promote platelet aggregation and calcification. Polymorphisms in one of these enzymes (ENPP1) was recently described to confer stroke protection to pediatric sickle cell patients and a lethal neonatal vascular calcification disorder called 'Generalized Arterial Calcification of Infancy' (GACI). Insights into this pathway allowed us to engineer a curative recombinant biologic which corrects disease sequela in GACI, which are moving into patients in collaboration with a company we founded (Inozyme Pharma). We have also identified a form of early onset osteoporosis associated with ENPP1 deficiency, and are investigating the role of ENPP1 in low bone mass and increased tissue calcification, a medical condition called 'Paradoxical Mineralization' which occurs in the general medical population in conditions such as aging and chronic kidney disease. We have recently expanded our research into enzyme biologics as therapeutics for oncology and autoimmune indications.
Medical Subject Headings (MeSH)
Academic Achievements & Community Involvement
Clinical Care
Overview
Demetrios Braddock, MD, PhD, is a pathologist who specializes in diagnosing blood cancers and diseases, especially a rare disease called generalized arterial calcification of infancy (GACI). As an undergraduate student, Dr. Braddock discovered that he enjoyed the creativity of research, in addition to possibility of helping patients. He decided to pursue a PhD during his medical training. “I enjoy working at the interface of what we know and don’t know, and expanding that border to advance medicine,” he says.
Since coming to Yale, Dr. Braddock has led research in his laboratory on a particular molecule called the ENPP enzyme. Enzymes, produced by cells in the body, serve as catalysts for different biological functions. The family of ENPP enzymes in particular help with blood vessel development and bone mineralization. Patients suffering from GACI usually have calcium deposits built up within their blood vessels, which interfere with blood flow. Dr. Braddock has developed biologic drugs that serve as enzyme replacement therapies to address rare diseases. “I will get phone calls from physicians all over who want more information about diagnosing GACI and who want to learn more about it,” he says.
For him, patient care is one of the most significant motivators in his research lab and in the clinic, when he is examining a patient sample for evidence of disease. “The physician cannot begin treatment of a patient without the correct diagnosis,” he says. “That’s where we come in and try to get the accurate clinical diagnosis for what we see microscopically.”
At Yale School of Medicine, Dr. Braddock is an associate professor of pathology.
Clinical Specialties
Board Certifications
Hematology (Pathology)
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2012
Anatomic Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2000
News & Links
Media
News
- July 11, 2024Source: Yale Ventures
11 Yale Projects Receive Awards from the Colton Center for Autoimmunity
- June 20, 2024Source: Yale News
New Enzyme Developed at Yale Offers Hope for Patients With Lupus
- April 17, 2024
Demetrios Braddock, MD, PhD, Named Recipient of 2024 Harrington Discovery Institute Scholar-Innovator Award
- March 25, 2024
Yale Pathology Research in Progress: ‘A Rite of Passage’